[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled …
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
…, L Bates, A Batten, K Beadon, R Beckley, D Bellamy… - The Lancet, 2020 - thelancet.com
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
[HTML][HTML] T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
…, R Morter, A Flaxman, D Wright, D Bellamy… - Nature medicine, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
[HTML][HTML] Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials …
…, L Bates, K Beadon, R Beckley, J Bell, D Bellamy… - The Lancet, 2021 - thelancet.com
Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …
immunity in some countries as the interval between the first and second dose becomes …
[HTML][HTML] Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled …
Background Stalled progress in controlling Plasmodium falciparum malaria highlights the
need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine …
need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine …
[HTML][HTML] Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
…, MK Verheul, PK Aley, B Angus, D Bellamy… - Nature medicine, 2021 - nature.com
More than 190 vaccines are currently in development to prevent infection by the novel severe
acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing …
acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing …
[HTML][HTML] Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised …
MS Datoo, HM Natama, A Somé, D Bellamy… - The Lancet Infectious …, 2022 - thelancet.com
Background Malaria is a leading cause of morbidity and mortality worldwide. We previously
reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified …
reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified …
[HTML][HTML] Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non …
…, M Bittaye, A Flaxman, FR Lopez, D Bellamy… - The Lancet Infectious …, 2020 - thelancet.com
Background Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection
continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. …
continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. …
